All In Biotech

Drug Trial Radar · NCT04155580

A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase 1, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Last checked: Nov 19, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

68

Actual

Start

Jun 12, 2020

Primary completion

Jan 14, 2022

Study completion Jan 14, 2022

Sponsor

Lead sponsor
Astex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, pharmacokinetics (PK), and efficacy of ASTX660 when given alone and in combination with ASTX727 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML). The duration of the study is expected to be approximately 30 months.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • ASTX660Drug

    Capsule for oral administration

  • ASTX727Drug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety Assessment: Number of participants with treatment-emergent adverse events (TEAEs)Time frame: Up to 30 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • University of California San Francisco

    San Francisco, California

  • Smilow Cancer Hospital

    New Haven, Connecticut

  • Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Northside Hospital - The Blood and Marrow Transplant Group of Georgia

    Atlanta, Georgia

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Franciscan Health Indianapolis (Blood and Marrow Transplantation)

    Indianapolis, Indiana

  • The University of Kansas Clinical Research Center

    Fairway, Kansas

  • Mayo Clinic

    Rochester, Minnesota

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • New York University Langone Health

    New York, New York

  • Mount Sinai Medical Center

    New York, New York

  • Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • Vanderbilt - Ingram Cancer Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.